Nottingham Guardian - Johnson & Johnson temporarily halts Covid-19 vaccine output: report

NYSE - LSE
CMSD 1.01% 23.87 $
NGG 0.86% 68.57 $
RIO 0.94% 62.48 $
CMSC 0.51% 23.78 $
AZN 2.34% 82.11 $
JRI 0.22% 13.54 $
SCS 0.36% 16.83 $
BCC -2.16% 83.97 $
BTI -0.29% 55.08 $
RYCEF 2.37% 14.74 $
GSK 1.02% 39.36 $
RBGPF 0% 71.48 $
BCE 0.41% 24.53 $
BP -2.23% 34.46 $
VOD -0.17% 11.7 $
RELX 0.83% 45.82 $
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.

Text size:

The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.

J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.

The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.

J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.

"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.

J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.

But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.

Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.

L.Bohannon--NG